Two weeks after Eli Lilly unveiled data showing its COVID-19 antibody cocktail of bamlanivimab and etesevimab slashed the risk of death and hospitalization for high-...

In the PD-1/L1 field, Merck & Co.’s Keytruda, Roche’s Tecentriq, and Pfizer and Merck KGaA’s Bavencio all have their clinical wins in different bladder cancer po...

MLM Medical Labs (“MLM”) is pleased to announce that Scott Houlton has joined the company as the new Chief Executive Officer and Roger Gasper as the Chief Financia...

Earlier this year, Jazz Pharmaceuticals floated a "dramatic" shift to new drug revenue by 2022—a plan buoyed by its own cancer and sleep disorder launches in 2019 and...

Amgen is cutting "several hundred" jobs, and its U.S. sales teams are bearing the brunt of it. The California-based drugmaker confirmed Wednesday that it is shrinking...

As Biogen nears a pivotal FDA decision on its closely watched Alzheimer’s disease drug candidate, other parts of the company’s business are sputtering—outlining just ...

When AbbVie won FDA approval for its next-generation immunology drugs Skyrizi and Rinvoq in 2019, the company had high hopes that the drugs could fill what threatened...

While supply constraints have hung over the rollout of the AstraZeneca COVID-19 vaccine in Europe, last week, CEO Pascal Soriot offered one way officials could make t...

One major concern over emerging coronavirus variants focuses on their impact on the efficacy of existing vaccines. But drugmakers appear to have countermeasures in th...

When Moderna first tapped Swiss CDMO juggernaut Lonza to crank out its COVID-19 vaccine, the partners set the goal to eventually hit 600 million to 1 billion doses pe...